Patent classifications
C07F9/5325
CYCLOALKANE-FUSED POLYCYCLIC AROMATIC COMPOUND
According to the present invention, options for materials for organic devices such as materials for organic EL elements are increased by addition of a cycloalkane, by condensation, to a polycyclic aromatic compound in which a plurality of aromatic rings are linked together by boron atoms, oxygen atoms, and the like. By using a novel cycloalkane-condensed polycyclic aromatic compound as a material for an organic EL element, for example, an organic EL element having excellent emission efficiency and element life is provided.
3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES
The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, R.sup.w is —NR.sup.10SO.sub.2R.sup.12; either a) R.sup.x and R.sup.y are F and R.sup.z and R.sup.zz are H; or b) R.sup.x, R.sup.y and R.sup.zz are independently halogen and R.sup.z is H; R.sup.5 is substituted phenyl or pyrimidinyl.
##STR00001##
HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device including the same.
PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLR8, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency.
PHOSPHORUS-CONTAINING SILANE COMPOUND, METHOD OF MAKING THE SAME, RESIN COMPOSITION AND ARTICLE MADE THEREFROM
A phosphorus-containing silane compound has a structure of SiR.sub.1(R.sub.2).sub.n(R.sub.3).sub.3-n, wherein R.sub.1 is a phenyl group, R.sub.2 is a vinyl group, R.sub.3 each independently is a structure of Formula (I) or Formula (II), and n is 1 or 2. Moreover, a method of making the phosphorus-containing silane compound, a resin composition including the phosphorus-containing silane compound and a resin additive and an article made from the resin composition are described. The article includes a prepreg, a resin film, a laminate or a printed circuit board, wherein one or more properties including Z-axis ratio of thermal expansion, copper foil peeling strength, inner resin flow, branch-like pattern, dielectric constant, dissipation factor and flame retardancy may be improved.
##STR00001##
METHOD FOR PRODUCING MAXACALCITOL, AND INTERMEDIATE THEREFOR
A new and improved method for preparing maxacalcitol and an intermediate therefor is provided. The method is an efficient and cost-effective process for preparing maxacalcitol and an intermediate therefor.
INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD)
- Simon Giroux ,
- Michael Philip CLARK ,
- Michael Aaron Brodney ,
- Philippe Marcel Nuhant ,
- Emily Elizabeth ALLEN ,
- Robert Francis FIMOGNARI, Jr. ,
- Mariam ZAKY ,
- Michael John BOYD ,
- David D. DEININGER ,
- Hu ZHANG ,
- Hongbo DENG ,
- Philip Noel COLLIER ,
- Brad MAXWELL ,
- Nathan D. WAAL ,
- Steven M. RONKIN ,
- Jian Wang ,
- Qing TANG ,
- Gabrielle Simone FLEMING ,
- Peter Jones ,
- Diane Marie BOUCHER ,
- Lev T.D. FANNING ,
- Amy B. HALL ,
- Dennis James HURLEY ,
- Mac Arthur Johnson, Jr. ,
- John Patrick Maxwell ,
- Rebecca Jane SWETT ,
- Timothy Lewis TAPLEY ,
- Stephen A. THOMSON ,
- Veronique DAMAGNEZ ,
- Kevin Michael Cottrell ,
- Upul Keerthi BANDARAGE
Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).
WIDE BANDGAP PEROVSKITE QUANTUM DOTS IN A PEROVSKITE MATRIX AND PROCESS FOR PREPARING SAME
The present invention provides quantum dot (QD)-in-matrix materials for use in blue light emitting diodes, wherein the QD-in-matrix material comprises a plurality of quantum dots embedded in a doped lead perovskite matrix.
COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME
The present specification relates to a compound represented by Chemical Formula 1, and an organic light emitting device including the same.
Compound and organic electro-optical device containing the same
Provided are a compound and an organic electro-optical device containing the same. The compound has a structure represented by Formula I. The organic electro-optical device comprises an anode, a cathode, and at least one organic thin film layer located between the cathode and the anode. The molecule of the compound provided by the present disclosure has higher rigidity, a large conjugated system, a deeper LUMO energy level, a higher triplet energy level and good molecular stability, and is not easy to crystallize, and thus the compound can be used as an electron transport material or a hole blocking material of the organic electro-optical device, facilitating the reduction of the turn-on voltage of the device, the improvement of current efficiency and the increase of service life.